- Shanghai Pharma’s net income for the first quarter is 1.54 billion yuan, marking an increase of 1.5% year over year.
- The operating revenue is reported at 70.15 billion yuan, which is a six percent increase compared to the previous year.
- Earnings Per Share (EPS) are at 42 RMB cents, indicating an increase from 41 RMB cents on a year-on-year basis.
- The company stock has received 11 buy ratings, no hold ratings, and just one sell rating.
- All comparisons made to past results are based on the values reported by the company in their original disclosures.
`
A look at Shanghai Pharmaceuticals Holding Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 5 | |
| Dividend | 5 | |
| Growth | 3 | |
| Resilience | 3 | |
| Momentum | 5 | |
| OVERALL SMART SCORE | 4.2 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Shanghai Pharmaceuticals Holding Co., Ltd, a company known for manufacturing pharmaceuticals in China, has garnered high Smart Scores across various factors. With top scores in Value and Dividend, indicating strong financial health and attractive dividend payouts, the company shows stability and profitability in the long run. Although scoring slightly lower in Growth and Resilience, Shanghai Pharmaceuticals Holding still demonstrates resilience and potential for growth in the competitive pharmaceutical industry. With a Momentum score of 5, the company showcases strong market momentum and investor interest, further reinforcing its positive long-term outlook.
In summary, Shanghai Pharmaceuticals Holding is a key player in the pharmaceutical sector, specializing in the development and sale of a wide range of medicines and healthcare products across China. With exceptional scores in Value, Dividend, and Momentum, the company is poised for continued success and steady performance in the market, making it an attractive prospect for investors seeking a reliable and profitable investment opportunity.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
